key: cord-1004535-a16qwqz1 authors: KONU, Y. R.; Gbeasor-Komlanvi, F.; Yerima, M.; Sadio, A. J.; Tchankoni, M. K.; Zida-Compaore, W. I.; Nayo-Apetsianyi, J.; Afanvi, K.; Agoro, S.; Salou, M.; Landoh, D. E.; Nyansa, A.; Boko, E.; Mijiyawa, M.; Ekouevi, D. K. title: Prevalence of severe adverse events in health professionals after receiving the first dose of the COVID-19 vaccination in Togo, March 2021 date: 2021-04-20 journal: nan DOI: 10.1101/2021.04.20.21254863 sha: 23f4089a3e272137669336832689c1f733fb66b1 doc_id: 1004535 cord_uid: a16qwqz1 Introduction: Covid-19 vaccines can cause adverse events (AE) that can lead to increased hesitation or fear of vaccination. This study aims at estimating the prevalence of severe adverse events (SAEs) and their associated factors among health professionals (HPs) vaccinated with COVISHIELD(TM) vaccine in Togo. Methods: A cross-sectional study was conducted from March 13th to 19th, 2021 in Togo among HPs who received the first dose of vaccine. An online self-administered questionnaire was used to collect data on sociodemographic characteristics and vaccination. SAEs were defined as one resulting in hospitalization, medical consultation, or inability to work the day following the administration of the vaccine. Regression analysis were performed to assess factors associated with SAEs. Results: A total of 1,639 HP (70.2% male) with a median age [IQR] of 32 years [27-40] participated. At least one AE was reported among 71.6% (95%CI= [69.3-73.8]). The most commonly reported AEs were pain at the injection site (91.0%), asthenia (74.3%), headache (68.7%), soreness (55.0%), and fever (47.5%). An increased libido was also reported in 3.0% of HP. Among HP who experienced AEs, 18.2% were unable to go to work the day after vaccination, 10.5% consulted a medical doctor, and 1.0% were hospitalized. The SAE prevalence was 23.8% (95%CI= [21.8-25.9]). Being <30 years (aOR=5.54; p<0.001), or 30-49 years (aOR=3.62; p<0.001) and being female (aOR=1.97; p<0.001) were associated with SAEs. Conclusion: Despite the occurrence of SAEs, current data collected in Togo about adverse events are reassuring with COVISHIELD(TM) vaccine and how they could be managed. Keywords: Severe adverse event, COVID-19, vaccine, prevalence, health professionals, Togo. Coronavirus disease 2019 (COVID-19) was first described in China in December 2019 70 [1] and resulted in the declaration of a pandemic in January 2020 [2] . As of March 24, 71 2021, more than 120 million cases of COVID-19 infections, with more than 2 million 72 deaths, were reported worldwide [3] . 73 No cure or vaccine was available until December 2020. Therefore, controlling the 74 infection to prevent the spread of COVID-19 was considered the only intervention [4] . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 20, 2021. ; https://doi.org/10.1101/2021.04.20.21254863 doi: medRxiv preprint allocation of 156,000 doses of the SII-AstraZeneca (COVISHIELD TM ) vaccine [9] Despite the awareness campaign on the importance of vaccination, several factors 110 contribute to limiting the adherence of the population to this intervention. These 111 include: i) the relative speed of discovery and availability the of vaccines, ii) the use of 112 new technologies never before deployed in humans, and iii) the lack of hindsight 113 regarding the safety of vaccines that are available. As a result, false information has been circulating about these new vaccines and has 115 contributed to the growing anxiety and vaccine hesitancy associated with a fear of 116 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) [15] . In parallel with the surveillance of 122 adverse events following immunization which is ensured by the pharmacovigilance 123 service of the Ministry of Health, this study was launched to quickly document adverse 124 events to reassure the population. Our objective was to estimate the prevalence of CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) 138 The target population included all HPs who received the first dose of the 139 COVISHIELD TM vaccine during the first phase of the vaccination campaign in Togo. For the purpose of this study, a health professional was defined as a professional who 141 works or is affiliated with the health sector, including workers from health administration 142 and logistics, clinical settings, and community health workers. The inclusion criteria for 143 eligible participants were: (i) being a health professional aged 18 years and older; and 144 (ii) having received the first dose of vaccine. The sample size of participants was calculated using a single proportion population 146 formula with a 95% confidence level. In the absence of previous studies on the severity 147 of the adverse events of the vaccine against COVID-19, we hypothesized that 10% of 148 the participants would experience at least one severe adverse event with a 2% margin 149 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 20, 2021. 163 The main outcome was the severity of reported adverse events. Adverse events were 164 grouped into three categories: severe (presence of adverse events resulting in self-165 reported hospitalization, seeking medical consultation, and inability to work the day 166 following the administration of the vaccine), moderate (presence of adverse events 167 without hospitalization, consultation or impact on working ability), and no side effects. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 20, 2021. <0.20 in univariable analysis were considered for the full multivariable models, which 178 were subsequently finalized using a stepwise, backward elimination approach (p-value 179 <0.05). Predictor variables were selected as those found to be relevant according to (Table 1) . ). An increase in libido was also reported in 3.0% of the participants (Figure 1 ). Of the participants who experienced adverse events, 18.2% were unable to go to work 203 the day after vaccination, 10.5% consulted a medical doctor, and 1.0% were 204 hospitalized. Thus, the prevalence of SAEs was 23.8% (95% CI = [21.8-25.9]). 206 Overall, medication use after vaccination was higher among participants with SAEs 207 (p<0.001). The use of analgesics by participants with SAE was 62.3% vs 39.0% for 208 participants with moderate events and 5.2% for those reporting no events (Table 2) . 210 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 20, 2021. ; https://doi.org/10.1101/2021.04.20.21254863 doi: medRxiv preprint A total of 67.5% of survey participants expressed concern about long-term adverse 211 events, and this concern was more pronounced among women than men (74.2% vs. 212 64.7%, p<0.001). Approximately one out of ten participants (10.9%) said they were not 213 ready to take the second dose of the vaccine (Table 3) . (Table 4) . Using the second definition of SAEs, the prevalence of SAEs was estimated at 10.6% participants expressed concern about long-term adverse events, and one out of ten 280 declared they were not ready to take the second dose of the vaccine. These results This study presents some limitations. We cannot exclude selection bias due to our 285 sampling method. Another limitation is that data collection was based on a declarative 286 approach. However, given that the participants were HPs, the reported effects are 287 probably consistent with reality. Finally, we used an operational definition to define SAE. This is a composite variable 289 including absence from work the day after vaccination, medical consultation and 290 hospitalization due to adverse events. This definition probably led to an overestimation 291 of SAE, but this operational definition seems appropriate in the Togolese context. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 20, 2021. A Novel Coronavirus 324 from Patients with Pneumonia in China Statement on the second meeting of the 327 International Health Regulations (2005) Emergency Committee regarding the 328 outbreak of novel coronavirus (2019-nCoV) 330 second-meeting-of-the-international-health-regulations-(2005)-emergency-331 committee-regarding-the-outbreak-of-novel-coronavirus WHO Coronavirus (COVID-19) Dashboard Initial impacts of global risk mitigation measures taken during the 336 combatting of the COVID-19 pandemic Overview of Public Health and Social 338 Measures in the context of COVID-19 172 countries and multiple candidate vaccines engaged in COVID-19 vaccine 342 Global Access Facility World Health Organization (WHO) WHO issues its first emergency use 349 validation for a COVID-19 vaccine and emphasizes need for equitable global 350 access Global Alliance for Vacccination and Immunization (GAVI). COVAX roll-out -355 WHO recommendation Serum Institute of 362 WHO -Prequalification of Medical Products (IVDs, Medicines Vaccines and Immunization Devices, Vector Control) COVID-19 national deployment and vaccination plan: Submission and review 368 process Hygiène Publique et de 372 l'Accès Universel aux Soins. Epidémie de COVID-19 au Togo-Rapport de 373 situation N°381 au 28 mars 2021 COVID-19 Ministère de santé, de l'hygiène publique et de l'accès 377 universel aux soins. Vaccination du personnel de santé du pays contre la 378 COVID-19 (Bulletin d'information N°2). 2021. 4p. 379 16. World Bank, Data Bank Direction Générale de la Statistique et de la Comptabilité 384 Général de la Population et de l'Habitat (4ième RGPH4) COVID-19 vaccines: 388 comparison of biological Requests of 392 medical examinations after pneumococcal & influenza vaccination in the elderly Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine 402 administered in a prime-boost regimen in young and old adults (COV002): a 403 single-blind, randomised, controlled, phase 2/3 trial Risk Factors of Healthcare 406 Workers With Coronavirus Disease 2019: A Retrospective Cohort Study Designated Hospital of Wuhan in China Assessment of self-medication practices in the context 411 of the COVID-19 outbreak in Togo Age-413 associated changes in the impact of sex steroids on influenza vaccine 414 responses in males and females. Npj Vaccines First Month of COVID-19 Vaccine Safety Monitoring -United States Landman 420 AB, et al. Acute Allergic Reactions to mRNA COVID-19 Vaccines What to Expect 427 after Getting a COVID-19 Vaccine [Internet]. Centers for Disease Control and 428 Prevention vaccine AstraZeneca analysis print NSAIDs: non-steroidal anti-inflammatory drugs *Chi-squared test